Praxis Precision Medicines to Showcase Advances in Cancer Treatment at Upcoming April Conferences

PRAXIS Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with genetically defined diseases, announced today that it will participate in two upcoming conferences in April.

The company will present at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place from April 1-5 in Orlando, Florida. During the meeting, Praxis will share updates on its lead candidate, PRA600, a precision medicine targeting the treatment of patients with advanced solid tumors.

Additionally, Praxis will also present at the 2023 European Hematology Association (EHA) Annual Congress, taking place from April 13-16 in Vienna, Austria. The company will provide an update on its pipeline of precision medicines for patients with genetically defined blood disorders.

"We are excited to share our latest research and progress with the scientific community at these premier conferences," said Dr. [Name], CEO of Praxis Precision Medicines. "Our team is committed to advancing the field of precision medicine and improving patient outcomes, and we look forward to engaging with the scientific community to further this mission."

Praxis Precision Medicines is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients with genetically defined diseases. The company's pipeline of precision medicines targets genetically defined diseases across multiple therapeutic areas, including oncology and hematology. For more information, please visit www.praxispmed.com.